Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 25, 2025 10:01 ET | Source: Research and Markets

PD-1 Resistant Head and Neck Cancer Market Research Report 2025-2030: Cracking the Code of Immunotherapy Resistance - How Sox9 and Anxa1 Shape the Tumor-Immune Standoff

Dublin, Nov. 25, 2025 (GLOBE NEWSWIRE) -- The "PD-1 Resistant Head and Neck Cancer - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market...
November 19, 2025 10:06 ET | Source: Research and Markets

Head and Neck Squamous Cell Carcinoma Market Research Report 2025-2035: Sanofi, Sun Pharma, and Eli Lilly Lead Through the Development of New Drugs, Clinical Trials, Combination Treatment Strategies

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Head and Neck Squamous Cell Carcinoma Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast,...
October 22, 2025 07:00 ET | Source: Galera Therapeutics

Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million

Galera Therapeutics Announces Acquisition of Avasopasem and the Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million
July 24, 2025 04:51 ET | Source: Research and Markets

Radiation Oncology Strategic Research Report 2025 | Market to Reach $10.2 Billion by 2030 - Surge in Awareness Campaigns on Early Cancer Detection Supports Growth

Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The "Radiation Oncology - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Radiation...
June 02, 2025 08:00 ET | Source: PDS Biotechnology Corporation

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

PDS Biotech announced the publication of three Versamune® HPV abstracts that were presented during the Head and Neck Cancer Poster Session at ASCO 2025.
May 27, 2025 08:45 ET | Source: Vaccinex, Inc.

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

ROCHESTER, N.Y., May 27, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer’s...
November 26, 2024 05:18 ET | Source: Research and Markets

Asia-Pacific Radiation Oncology Market Analysis Report 2025-2030 - External Beam Radiation Therapy (EBRT) Dominated the Market with a Revenue Share of 35.9% in 2024

Dublin, Nov. 26, 2024 (GLOBE NEWSWIRE) -- The "Asia-Pacific Radiation Oncology Market Size, Share & Trends Analysis Report by Type (External Beam Radiation Therapy, Internal Beam Radiation...
November 21, 2024 05:35 ET | Source: Research and Markets

Clinical Nutrition for Cancer Care: Assessment of the Global Market with Regional Growth Projections to 2033 and Analysis of Leading Industry Players Including Pfizer, Bayer, and Abbott Nutrition

Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Clinical Nutrition for Cancer Care Global Market 2024" report has been added to ResearchAndMarkets.com's offering.The clinical nutrition for cancer...
November 05, 2024 08:30 ET | Source: Vaccinex, Inc.

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

ROCHESTER, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
June 04, 2024 13:00 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with...